BioSpace News Archive

Nicox SA, an international ophthalmology company, announced that new nonclinical data on NCX 470 demonstrating greater intraocular pressure lowering than Lumigan® upon both single and repeated dosing in an in vivo nonclinical model has been published in the peer-reviewed Journal of Ocular Pharmacology and Therapeutics.

Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, emerged from stealth with the announcement of its successful Series A fundraise.

GPCR Therapeutics, Inc., a clinical-stage international biopharmaceutical company, announces it enters into an out-licensing agreement with Bridge Biotherapeutics for the CXCR4-LPA1 inhibitor combination method of treatment.

The Japan-based Global Health Innovative Technology Fund announced that it will invest approximately US$3.3 million in a global multicenter Phase III clinical trial project led by Fosun Pharma for a triple artemisinin combination drug against malaria in Africa and Southeast Asia, to accelerate the development and commercialization of this new drug.

Agomab Therapeutics NV announced that it has dosed the first subject in a first-in-human Phase 1 clinical study of AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5.

Delivering the two-dose mpox vaccine, called JYNNEOS, in smaller than the usual FDA-approved doses, and by injection between layers of the skin rather than by the standard route under the skin, produced a detectable immune response, a new study shows.

Biogen Inc. and Sage Therapeutics, Inc. announced ZURZUVAE™ 50 mg CIV is now available by prescription for the treatment of postpartum depression for adults in the United States, with product already at specialty pharmacies and delivered to patients.

Kraig Biocraft Laboratories, Inc. announces the early start to the production season with the successful manufacture and delivery of the most recent batch of recombinant spider silk.

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.

Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, has won back-to-back global recognitions for its commitment and progress on sustainability and Environment Social and Governance agenda.